Skip to content

A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens

A Study to Evaluate the Safety and Efficacy of a Kalifilcon A Contact Lens for Daily Disposable Use

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04158466
Enrollment
252
Registered
2019-11-08
Start date
2019-05-31
Completion date
2019-11-12
Last updated
2020-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact Lens Wear

Keywords

Disposable Contact Lenses, Soft Contact Lens, Soft Contact Lenses

Brief summary

This study is to evaluate the safety and efficacy of a new silicone hydrogel daily disposable contact lens, kalifilcon A compared to the Bausch + Lomb Biotrue ONE day® daily disposable contact lens when worn by current soft contact lens wearers on a daily disposable wear basis.

Detailed description

Approximately 247 participants (494 eyes) will be enrolled in at approximately 20 investigative sites in the United States (US). A minimum of 20% of the randomized participants will be of Japanese descent (for example, both maternal and paternal grandparents born in Japan).

Interventions

DEVICEKalifilcon A Daily Disposable Contact Lenses

Contact lens

DEVICEBiotrue ONEday Daily Disposable Contact Lenses

Contact lens

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF) and provide authorization as appropriate for local privacy regulations. * Participants must be myopic and require lens correction from -0.25 to -6.00 Diopter (D) with 0.25 D steps, in each eye. * Participants must be correctable through spherocylindrical refraction and with soft spherical contact lenses to 40 letters (0.14 logMAR) or better (2 meters distance, high-contrast chart) in each eye. * Participants must be free of any anterior segment disorders. * Participants must be adapted soft contact lens wearers and willing to wear their study lenses for at least 8 hours per day at least 5 days per week on a daily disposable wear basis for approximately 3 months. * Participants must be willing and able to comply with all treatment and follow-up/study procedures, as well as willing and able to refrain from using any other contact lenses or solutions other than those provided for the duration of the study.

Exclusion criteria

* Participation in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or during the period of study participation. * Participants who are women of childbearing potential (those who are not surgically sterilized or postmenopausal) are excluded from participation in the investigation if they are currently pregnant, plans to become pregnant during the study, or is breastfeeding * Participants who have worn gas permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last 3 months. * Participants with any systemic disease currently affecting ocular health or in the Investigator's opinion may have an effect on ocular health during the course of the study. * Participants using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance. * Participants with an active ocular disease or who are using any ocular medication. * Participants who currently wear monovision, multifocal, or toric contact lenses. * Participants with an ocular astigmatism of greater than 1.00 D in either eye. * Participants with anisometropia (spherical equivalent) of greater than 2.00 D. * Participants with any Grade 2 or greater finding during the slit lamp examination. Participants with corneal infiltrates of any grade. * Participants with any Present finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear. * Participants with any scar or neovascularization within the central 6 millimeters (mm) of the cornea. * Participants who are aphakic. * Participants who are amblyopic. * Participants who have had any corneal surgery (for example, refractive surgery). * Participants who are allergic to any component in the study care products. * The participant is an employee of the investigative site. * The participant, or a member of the participant's household, is an Ophthalmologist, an Optometrist, an Optician, or an Ophthalmic Assistant/Technician. * The participant, or a member of the participant's household, is an employee of a manufacturer of contact lenses or contact lens care products (for example, Alcon, Bausch + Lomb, Ciba Vision, CooperVision, Johnson & Johnson). * The participant, or a member of the participant's household, is an employee of a market research firm.

Design outcomes

Primary

MeasureTime frameDescription
Mean logMAR Contact Lens Visual Acuity3 monthsVisual acuity (VA) will be reported as letters read correctly, and the letters read will be converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant will read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters will be recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity will be averaged across visits.
Proportion of Participants With Slit Lamp Findings Greater Than Grade 23 monthsDuring an examination of both eyes without lenses, graded slit lamp findings will be assessed for each eye using Grades 0 (none), 1 (trace), 2 (mild), 3 (moderate), and 4 (severe). Using only the non-missing observations from all visits without imputation, each eye will be classified with respect to findings greater than Grade 2 at any visit (Absent or Present). Epithelial edema, epithelial microcysts, corneal staining, limbal Injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be evaluated.

Countries

United States

Participant flow

Recruitment details

There were 252 participants randomized but 251 participants received treatment. Participants are summarized by actual treatment group received.

Participants by arm

ArmCount
Kalifilcon A Daily Disposable Contact Lenses
Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study. Kalifilcon A Daily Disposable Contact Lenses: Contact lens
124
Biotrue ONEday Daily Disposable Contact Lenses
Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study. Biotrue ONEday Daily Disposable Contact Lenses: Contact lens
127
Total251

Baseline characteristics

CharacteristicKalifilcon A Daily Disposable Contact LensesBiotrue ONEday Daily Disposable Contact LensesTotal
Age, Continuous35.9 years33.6 years34.7 years
Average Daily Wear Time13.5 hours per day13.4 hours per day13.4 hours per day
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
60 Participants55 Participants115 Participants
Race (NIH/OMB)
Black or African American
5 Participants8 Participants13 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
59 Participants64 Participants123 Participants
Sex: Female, Male
Female
88 Participants94 Participants182 Participants
Sex: Female, Male
Male
36 Participants33 Participants69 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1240 / 127
other
Total, other adverse events
0 / 1240 / 127
serious
Total, serious adverse events
0 / 1240 / 127

Outcome results

Primary

Mean logMAR Contact Lens Visual Acuity

Visual acuity (VA) will be reported as letters read correctly, and the letters read will be converted to logarithm of the minimum angle of resolution (logMAR) acuity. The participant will read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters. The total number of correct letters will be recorded. A decrease in the number of correct letters indicates a decrease in visual acuity. Acuity will be averaged across visits.

Time frame: 3 months

Population: The per protocol population consisted of randomized without important (major) protocol deviations. It is a subset of the participants randomized and treated.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Kalifilcon A Daily Disposable Contact LensesMean logMAR Contact Lens Visual Acuity-0.066 units on a scaleStandard Error 0.0034
Biotrue ONEday Daily Disposable Contact LensesMean logMAR Contact Lens Visual Acuity-0.060 units on a scaleStandard Error 0.0032
Primary

Proportion of Participants With Slit Lamp Findings Greater Than Grade 2

During an examination of both eyes without lenses, graded slit lamp findings will be assessed for each eye using Grades 0 (none), 1 (trace), 2 (mild), 3 (moderate), and 4 (severe). Using only the non-missing observations from all visits without imputation, each eye will be classified with respect to findings greater than Grade 2 at any visit (Absent or Present). Epithelial edema, epithelial microcysts, corneal staining, limbal Injection, bulbar injection, upper lid tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be evaluated.

Time frame: 3 months

ArmMeasureValue (COUNT_OF_UNITS)
Kalifilcon A Daily Disposable Contact LensesProportion of Participants With Slit Lamp Findings Greater Than Grade 20 eyes
Biotrue ONEday Daily Disposable Contact LensesProportion of Participants With Slit Lamp Findings Greater Than Grade 20 eyes

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026